

Applicants: Gotwals, et al.
Application No.: 09/423,018
Filed: October 12, 2000
Page 2 of 9

Docket No. A018 US

Claim Amendments:

Claims 1-4 (cancelled).

Claim 5 (allowed): An isolated TGF-beta fusion protein comprising amino acids 1 to 160 of SEQ ID NO: 8.

Claims 6-7 (cancelled).

Claims 8-9 (withdrawn).

Claim 10 (cancelled).

Claims 11-21 (withdrawn).

Claim 22 (new): A TGF- β RII fusion protein comprising: (1) a biologically active amino acid sequence which corresponds to all or all part of the extracellular region of native TGF- β RII and which is at least 60% homologous to SEQ ID NO: 9, or equivalents thereof, or naturally occurring variants thereto; and (2) a constant region of an immunoglobulin, wherein the fusion protein binds to TGF- β .

Claim 23 (new): The fusion protein of claim 22, wherein the constant region comprises IgG.

Claim 24 (new): The fusion protein of claim 23, wherein the constant region comprises IgG1.

Claim 25 (new): The fusion protein of claim 24, wherein the constant region comprises the hinge C_H2 or C_H3 portion of IgG1.

Claim 26 (new): The fusion protein of claim 22, wherein the biologically active amino acid sequence comprises amino acids 1 to 160 of SEQ ID NO: 9.

Claim 27 (new): A TGF- β RII fusion protein comprising: (1) a biologically active amino acid sequence which corresponds to all or part of the extracellular region of native TGF- β RII and which is at least 60% homologous to SEQ ID NO: 8, or equivalents thereof, or naturally occurring variants thereto; and (2) a constant region of an immunoglobulin, wherein the fusion protein binds to TGF- β .

Applicants: Gotwals, et al.
Application No.: 09/423,018
Filed: October 12, 2000
Page 3 of 9

Docket No. A018 US

Claim 28 (new): A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a fusion protein of claim 22.

Claim 29 (new): A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a fusion protein of claim 27.

Claim 30 (new): A TGF- β RII fusion protein comprising: (1) a biologically active amino acid sequence which is at least between about 5 to about 150 amino acid sequences in length and which includes at least between about 5 to about 150 contiguous amino acids of SEQ ID NO: 9, or an equivalent thereof; and (2) a constant region of an immunoglobulin, wherein the fusion protein binds to TGF- β .

Claim 31 (new): The fusion protein of claim 30, wherein the constant region comprises IgG.

Claim 32 (new): The fusion protein of claim 31, wherein the constant region comprises IgG1.

Claim 33 (new): The fusion protein of claim 32, wherein the constant region comprises the hinge C_H2 or C_H3 portion of IgG1.

C1
Claim 34 (new): A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a fusion protein of claim 30.

Claim 35 (new): A TGF- β RII fusion protein comprising: (1) a biologically active amino acid sequence which is at least between about 5 to about 150 amino acid sequences in length and which includes at least between about 5 to about 150 contiguous amino acids of SEQ ID NO: 8, or an equivalent thereof; and (2) a constant region of an immunoglobulin, wherein the fusion protein binds to TGF- β .

Claim 36 (new): The fusion protein of claim 35, wherein the constant region comprises IgG.

Claim 37 (new): The fusion protein of claim 36, wherein the constant region comprises IgG1.

Claim 38 (new): The fusion protein of claim 37, wherein the constant region comprises the hinge C_H2 or C_H3 portion of IgG1.

Applicants: Gotwals, et al.
Application No.: 09/423,018
Filed: October 12, 2000
Page 4 of 9

Docket No. A018 US

C1

Claim 39 (new): A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a fusion protein of claim 35.
